Impact of cyclosporine dose on long-term outcome after heart transplantation.
Valantine
H
H
Division of Cardiovascular Medicine, Stanford University School of Medicine, California 94305-5246.
Hunt
S
S
Gamberg
P
P
Miller
J
J
Luikart
H
H
D000206:Actuarial Analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003327:Coronary Disease / Q000453:epidemiology; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D016853:Muromonab-CD3 / Q000627:therapeutic use; D015995:Prevalence; D011336:Probability; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine